MRK · 8-K · 20260804PR090045

Market Demand Trends

Merck & Co., Inc. · 2026-08-04 · Importance 57 · Surprise 64

KEYTRUDA/KEYTRUDA QLEX sales increased 5% to $8.366 billion, driven by global uptake in earlier-stage triple-negative breast cancer, cervical, head and neck and bladder cancer indications, as well as metastatic urothelial cancer demand. WINREVAIR sales rose 75% to $588 million, reflecting continued U.S. uptake and early launches in Japan and Europe. Animal Health sales increased 8% to $1.775 billion, with growth in both livestock and companion-animal products, while BRAVECTO sales increased 7% to $359 million. GARDASIL/GARDASIL 9 sales rose 4% to $1.169 billion, primarily on higher demand in Asia Pacific and Europe.